BERLIN (AP) — The chief executive of CureVac said Thursday that interim results from late-stage testing of its coronavirus shot are “sobering,” but the German company aims to finish a final analysis within weeks that will determine whether it will still seek regulatory approval.
CureVac announced late Wednesday that the vaccine had shown an efficacy of 47% against COVID-19 of any severity, according to a partial review of data from its trial involving 40,000 participants in Latin America and Europe. This is below the World Health Organization threshold of 50%.
The biotechnology company said more than two dozen variants of the coronavirus were found in its trial across 10 countries, a fact that may have affected the outcome.
“The results are sobering,” said chief executive Franz-Werner Haas. “We recognize that demonstrating high efficacy in this unprecedented broad diversity of variance is quite challenging.”